Torisel
Generic name: temsirolimus
Treatment for: Renal Cell Carcinoma
FDA Grants Torisel NDA Priority Review Status
MADISON, N.J., December 19, 2006 -- Wyeth Pharmaceuticals, a division of Wyeth , announced today that the U.S. Food and Drug Administration (FDA) has accepted the file and granted priority review status to the Company's New Drug Application (NDA) for the investigational drug Torisel (temsirolimus). Wyeth Pharmaceuticals is seeking an indication for Torisel for the treatment of advanced renal cell carcinoma (RCC). A priority designation can be given to an NDA for a drug that, if approved, would be a significant improvement compared with existing treatments.
The FDA previously granted fast track designation and orphan drug status for investigational temsirolimus for the treatment of advanced RCC.
Torisel is the first mTOR (mammalian target of rapamycin) inhibitor to be filed for approval for the treatment of a cancer. It is an investigational drug that specifically inhibits the mTOR kinase, a protein that regulates cell proliferation, cell growth and cell survival.
"Renal cell carcinoma continues to be an extremely difficult-to-treat form of cancer, and there continues to be a need for new therapies. Torisel has demonstrated its potential to help meet that important medical need," says Lee F. Allen, M.D., Ph.D., Vice President of Oncology Clinical Research at Wyeth.
The registration dossier contains interim data from a three-arm, Phase 3 clinical trial of 626 patients who had received no prior systemic therapy. The results showed that Torisel significantly increased overall survival by 49 percent in patients with advanced RCC compared with interferon-alpha, a treatment for advanced RCC.
In the United States, Torisel will be available prior to FDA approval through an Expanded Access Program (EAP). For more information about the Torisel EAP in the United States, please call (800) 234-8423.
Related article:
- Wyeth Submits NDA and MAA for Torisel for the Treatment of Advanced Renal Cell Carcinoma October 6, 2006
Posted: December 2006
Related articles
- FDA Approves Torisel, a Targeted First-in-Class mTOR Inhibitor forthe Treatment of Advanced Kidney Cancer - May 31, 2007
- Wyeth Provides Update on FDA Review of the Torisel New Drug Application - April 6, 2007
- Wyeth Submits NDA and MAA for Torisel for the Treatment of Advanced Renal Cell Carcinoma - October 6, 2006
Torisel (temsirolimus) FDA Approval History
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.
